



## NEWS RELEASE

### BIOSENSORS CLARIFIES ON RECENT MEDIA REPORTS

**Singapore, 20 January 2016** – Biosensors International Group, Ltd. (“**Biosensors**” or the “**Company**”, Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, recently noticed certain media reports stating that “US FDA banned Biosensors International from importing products to the US”.

The Company wishes to clarify a few points. FDA placed Biosensors’ Critical Care Products on the Import Alert because it thought Biosensors International refused the scheduled routine inspection by the FDA by not responding to the notification letter within the required 5-day window. Biosensors received the letter on 21 December 2015 and responded that it would welcome the inspection on 11 January 2016. The delay was caused by administrative errors during the holidays.

Biosensors received confirmation from the FDA on 19 January 2016 that Biosensors International would be removed from the Import Alert based on the company’s willingness to be inspected. The Company also wishes to emphasize that Biosensors view all regulatory compliance and inspections with utmost importance, including the FDA.

###

#### **Media/Investor Relations Contact**

Tel: (65) 6213 5777

Email: [ir@biosensors.com](mailto:ir@biosensors.com)

#### **About Biosensors International Group, Ltd.**

Biosensors International Group, Ltd. develops, manufactures and markets innovative medical devices, aiming to improve patients’ lives through pioneering medical technology that pushes forward the boundaries of innovation. Founded in 1990, the Company was listed on the Mainboard of the Singapore Stock Exchange in 2005.

The Group currently operates through four business units (“BU”): the Cardiovascular BU, composed primarily of the BioMatrix™ & EXCEL™ families of drug-eluting stents, BioFreedom™ drug-coated stents, and stent technologies such as BA9™; the Cardiac Diagnostic BU, including Spectrum Dynamics products that offer advanced medical imaging and clinical solutions to help interventional cardiologists determine the most appropriate

treatment for patients; the Peripheral Intervention BU, offering solutions for the treatment of patients with peripheral arterial disease; and the Critical Care Products BU.

The Group has operations worldwide and is headquartered in Singapore.

For more information, please visit [www.biosensors.com](http://www.biosensors.com).

### **Forward-Looking Statements**

*Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.*